The US Food and Drug Administration (FDA) has awarded breakthrough therapy designation to uniQure's AMT-130 for Huntington's ...

SOM3355 (bevantolol hydrochloride) hit its objectives in a phase 2 trial in patients with Huntington's disease, improving the involuntary, jerky movements known as chorea that are a key symptom of ...

Ingrezza (valbenazine) is a prescription drug that’s used to treat tardive dyskinesia and chorea caused by Huntington’s disease. Ingrezza can cause mild to serious side effects. Examples ...

HDBuzz has ramped up to match the accelerating pace of Huntington’s disease research. April 2025 brought us insight on ...

Xenazine (tetrabenazine) is a brand-name oral tablet that’s prescribed for chorea (a movement disorder) in people with Huntington’s disease. If you have problems with side effects from ...

Each person living with Huntington’s disease shines in their own unique way ... These very common movement symptoms - known as chorea - are often seen in people with HD. There are a number of coping ...

Ingrezza (valbenazine) is a brand-name oral capsule prescribed for tardive dyskinesia and Huntington’s chorea. The cost of the drug with and without insurance can depend on several factors.

Qure's AMT-130 receives FDA Breakthrough Therapy designation for Huntington's disease, adding to Fast Track, RMAT, and Orphan ...

and FDA commitment involving senior managers Huntington’s disease is a rare, inherited neurodegenerative disorder that leads to motor symptoms including chorea, behavioral abnormalities and ...

uniQure noted that Huntington's disease, which results in chorea, cognitive decline, and behavioural abnormalities, affects approximately 70,000 people in Europe and the US, with many more at risk.